Urine biomarkers enable pancreatic cancer detection up to 2 years before diagnosis

The poor prognosis of pancreatic ductal adenocarcinoma (PDAC) is mainly attributed to late diagnosis. We assessed the predictive performance of our previously reported urine biomarker panel for earlier detection of PDAC (LYVE1, REG1B and TFF1) in prediagnostic samples, alone and in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Debernardi, Silvana, Blyuss, Oleg, Rycyk, Daria, Srivastava, Kirtiman, Jeon, Christie Y., Cai, Hui, Cai, Qiuyin, Shu, Xiao‐Ou, Crnogorac‐Jurcevic, Tatjana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789171/
https://www.ncbi.nlm.nih.gov/pubmed/36093581
http://dx.doi.org/10.1002/ijc.34287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789171/
https://www.ncbi.nlm.nih.gov/pubmed/36093581
http://dx.doi.org/10.1002/ijc.34287

Ejemplares similares